Fusion Antibodies (LON:FAB) Trading Up 3%

Fusion Antibodies plc (LON:FAB) traded up 3% on Wednesday . The company traded as high as GBX 3.40 ($0.04) and last traded at GBX 3.40 ($0.04). 1,009,924 shares were traded during mid-day trading, a decline of 7% from the average session volume of 1,082,811 shares. The stock had previously closed at GBX 3.30 ($0.04).

Fusion Antibodies Price Performance

The company’s 50 day moving average is GBX 3.23 and its 200-day moving average is GBX 3.66. The stock has a market cap of £3.24 million, a PE ratio of -37.78 and a beta of 0.49. The company has a current ratio of 3.26, a quick ratio of 2.36 and a debt-to-equity ratio of 3.23.

Insider Activity

In other Fusion Antibodies news, insider Simon Gordon Douglas purchased 150,000 shares of the firm’s stock in a transaction dated Monday, July 22nd. The stock was acquired at an average cost of GBX 3 ($0.04) per share, with a total value of £4,500 ($5,745.66). Company insiders own 10.36% of the company’s stock.

About Fusion Antibodies

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.